ClinicalTrials.gg
Drug

Maralixibat clinical trials

Also written LUM001 and TAK-625.

studies test it
23
open now
4
in phase 3
7
first study started
2013

How each study uses maralixibat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the maralixibat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 Sept 2021 · LIVMARLI · NDA 214662 (FDA, Drugs@FDA)
European Union
9 Dec 2022 · Livmarli · EMEA/H/C/005857 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Maralixibat
11
Formerly LUM001 and SHP625
4
LUM001 (Maralixibat)
4
Maralixibat chloride
2

Development codes

LUM001
6
TAK-625
2
SHP625
1

Studies by the year they started

22 studies that test it; most in 2014 (4); 1 more planned to start later

Studies that test maralixibat, by start year
YearStudies
20133
20144
20153
20181
20191
20202
20212
20232
20241
20252
20261

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
15
Phase 3
7
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 21 · Other 2

Mirum Pharmaceuticals, Inc. (19) · Takeda (2) · Imperial College London (1) · Children's Hospital Los Angeles (1)

Often tested with

Tested in the same studies.

Volixibat (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test maralixibat, phase 3 first.

Studies

Open first, then newest update. How each study uses maralixibat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 23

See all 23 studies that test maralixibat →

Codes

What other systems call maralixibat · ClinicalTrials.gg INT001908

  • MeSH (NLM) C000722912maralixibatConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) UYB6UOF69LMARALIXIBATConfirmed FDA, NLM, Wikidata
  • RxNorm 2571074One source FDA
  • Wikidata Q27291331maralixibatConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C170148MaralixibatOne source FDA
  • DrugBank DB16226One source Wikidata

Also registered as maralixibat chloride (UNII V78M04F0XC · RxNorm 2571073).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.